BioLargo Inc
OTC:BLGO
BioLargo Inc
BioLargo, Inc. engages in the provision of technology solutions for odor and moisture control, disinfection, and water treatment. The company is headquartered in Westminster, California and currently employs 27 full-time employees. The firm invents, develops, and commercializes platform technologies to solve environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds (VOC) control, air quality control and infection control. The company provides sustainable solutions for a range of industries and applications. The Company’s products include Advanced Oxidation System (AOS), Aqueous Electrostatic Concentrator (AEC), CupriDyne Clean industrial odor control product, Clyraguard Personal Protection Spray, and hand sanitizer. The firm provides its products through its subsidiaries, including ONM Environmental, Inc., BioLargo Water, Inc., BioLargo Water Investment Group, Inc., BioLargo Development Corp., BioLargo Engineering, Science & Technologies, LLC and Clyra Medical Technologies, Inc.
BioLargo, Inc. engages in the provision of technology solutions for odor and moisture control, disinfection, and water treatment. The company is headquartered in Westminster, California and currently employs 27 full-time employees. The firm invents, develops, and commercializes platform technologies to solve environmental problems like polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds (VOC) control, air quality control and infection control. The company provides sustainable solutions for a range of industries and applications. The Company’s products include Advanced Oxidation System (AOS), Aqueous Electrostatic Concentrator (AEC), CupriDyne Clean industrial odor control product, Clyraguard Personal Protection Spray, and hand sanitizer. The firm provides its products through its subsidiaries, including ONM Environmental, Inc., BioLargo Water, Inc., BioLargo Water Investment Group, Inc., BioLargo Development Corp., BioLargo Engineering, Science & Technologies, LLC and Clyra Medical Technologies, Inc.
Impairment Hit: BioLargo took a $3.85 million credit loss related to Pooph, leading to a significant net loss for the quarter.
Revenue Decline: Revenue for the 9 months fell by about 50% from $14 million to $7 million, mainly due to the Pooph setback.
Portfolio Resilience: Despite the Pooph loss, management emphasized the company's diversified portfolio and strong cash position of $4.5 million.
Clyra Nearing Commercialization: Clyra, focused on wound care, is at the end of its capital expenditure phase, with expectations for initial product orders and clinical data visibility by Q1 2026.
Battery Tech Progress: The company is advancing its transformative battery technology, has signed multiple MOUs, and is seeking financing to build battery factories, highlighting large market potential.
PFAS Breakthrough: BioLargo reported technical and cost reduction breakthroughs in PFAS treatment, positioning itself as a high-performing, cost-competitive solution provider.
Litigation Update: The company filed a lawsuit against Pooph to protect its IP and recover $3.9 million, asserting confidence in its legal position.
Optimism and Transparency: Management acknowledged investor frustration with slow business development but highlighted long-term value and progress across core assets.
